logo
Plus   Neg
Share
Email

AbbVie Announces Approval Of SKYRIZI In Japan - Quick Facts

AbbVie (ABBV) announced the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved SKYRIZI (risankizumab) for the treatment of plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis and psoriatic arthritis in adult patients who have an inadequate response to conventional therapies. The company noted that the approval is the first country approval in the world for SKYRIZI.

The European Medicines Agency's CHMP adopted a positive opinion for SKYRIZI for treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy in February 2019. SKYRIZI is currently under review with the U.S. FDA and a regulatory decision is anticipated in the first half of 2019.

SKYRIZI is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization of SKYRIZI globally.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT